View Older Stories View More Recent Stories

Jul 31, 2019 08:00AM Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
Jul 1, 2019 07:30AM Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes
Jun 11, 2019 07:04AM Zynerba Pharma (ZYNE) Granted New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
Jun 11, 2019 07:00AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
Jun 11, 2019 07:00AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
May 30, 2019 04:30PM Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds
May 29, 2019 06:48AM Zynerba Pharma (ZYNE) Commences Phase 2 Trial of Zygel in 22q11.2 Deletion Syndrome
May 29, 2019 06:45AM Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
May 29, 2019 06:45AM Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
May 28, 2019 11:30AM Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
May 8, 2019 12:12PM Merida Capital Adds Former Omnicom Group and Medco Health Solutions Executives to Operating Team
May 8, 2019 06:50AM Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
May 8, 2019 06:50AM Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
May 6, 2019 07:03AM Zynerba Pharma (ZYNE) Granted FDA Fast Track Status for Zygel
May 6, 2019 07:00AM Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
May 6, 2019 07:00AM Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel™ for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS)
Apr 2, 2019 10:00AM Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
Mar 11, 2019 06:50AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights
Mar 11, 2019 06:50AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights
Mar 11, 2019 02:50AM Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights
Mar 7, 2019 07:09AM Zynerba Pharma (ZYNE) Commences Phase 2 Trial of Zygel in Autism Spectrum Disorder
Mar 7, 2019 07:00AM Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
Mar 7, 2019 07:00AM Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
Feb 26, 2019 07:10AM Zynerba Pharma (ZYNE) Announces New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
Feb 26, 2019 07:00AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
Feb 26, 2019 07:00AM Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol
Feb 20, 2019 07:00AM Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors
Feb 5, 2019 10:00AM Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference
Dec 17, 2018 06:55AM Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
Dec 17, 2018 06:55AM Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
Dec 12, 2018 05:33PM Zynerba Pharma (ZYNE) Announces Sustained Improvements in Emotional, Behavioral Symptoms of FXS through 12 Months with ZYN002
Dec 12, 2018 05:30PM Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
Nov 20, 2018 08:00AM Zynerba Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
Nov 8, 2018 06:45AM Zynerba Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
Oct 11, 2018 10:47AM Zynerba Pharmaceuticals to Present at the 2018 BIO Investor Forum
Sep 26, 2018 09:00AM Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Aug 31, 2018 08:30AM Zynerba Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Aug 2, 2018 06:50AM Zynerba Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Aug 1, 2018 08:46AM Zynerba Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
Jul 31, 2018 07:30AM Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update
Jul 12, 2018 09:15AM Pre-Open Movers 07/12: (ZGNX) (GLMD) (CA) Higher; (ZN) (ACRX) (AVGO) Lower (more...)
Jul 12, 2018 07:31AM Zynerba Pharma (ZYNE) Reports New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
Jul 12, 2018 07:30AM Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
Jul 12, 2018 07:30AM Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
Jul 9, 2018 06:56AM Zynerba Pharma (ZYNE) Initiate Trial of ZYN002 in Fragile X Syndrome
Jul 9, 2018 06:55AM Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
Jul 9, 2018 06:55AM Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome
Jul 5, 2018 07:30AM Zynerba Pharma (ZYNE) Reports Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study
Jul 5, 2018 07:30AM Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study
May 31, 2018 08:00AM Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
View More Recent Stories View Older Stories